Skip to main content
  • Sign in
    Welcome !
    My account
    Logout

Celldex Therapeutics, Inc. (CLDX) Stock Forecast 2025 - AI Price Prediction & Analysis

Celldex Therapeutics, Inc. (CLDX) AI Stock Price Forecast & Investment Analysis

Celldex Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading Celldex Therapeutics, Inc. interactive price chart and technical analysis...

Celldex Therapeutics, Inc. (CLDX) - Comprehensive Stock Analysis & Investment Research

Company Overview & Business Profile

Celldex Therapeutics, Inc. (Stock Symbol: CLDX) is a leading company in the Life Sciences sector , specifically operating within the In Vitro & In Vivo Diagnostic Substances industry. The organization employs approximately 163 professionals worldwide . The company has established itself as an emerging investment opportunity with substantial growth potential.

Financial Performance & Key Metrics Analysis

Annual Revenue: $5 million generating a -891.9% net profit margin .

Market Capitalization: $1477 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -26.0% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Advanced AI Stock Prediction & Price Target Analysis

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Celldex Therapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Market Position & Competitive Advantage Analysis

Celldex Therapeutics, Inc. strategically competes in the highly dynamic In Vitro & In Vivo Diagnostic Substances marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities . , complemented by impressive -4.1% year-over-year cash flow growth. The company maintains a healthy 100.0% gross margin, indicating strong pricing power and operational efficiency.

Celldex Therapeutics, Inc. (CLDX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Celldex Therapeutics, Inc. stock analysis.

Loading Celldex Therapeutics, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Celldex Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Celldex Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Celldex Therapeutics, Inc.: With a P/E ratio of -10.12, the market sees the stock as potentially undervalued.

P/E Ratio -10.12x
P/B Ratio 2.25x
Market Cap $1477M
Dividend Yield 0.17%
EPS $-3.01
Book Value/Share $9.87
Revenue/Share $0.09
FCF/Share $-2.00
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Celldex Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Celldex Therapeutics, Inc.: An ROE of -26.0% indicates room for improvement in shareholder value creation.

ROE -26.0%
ROA -24.0%
ROIC -25.8%
Gross Margin 100.0%
Operating Margin -4757.3%
Net Margin -891.9%
EBT Margin -906.3%
Tax Rate 23.8%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Celldex Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Celldex Therapeutics, Inc.: A current ratio of 26.83 indicates strong liquidity.

Current Ratio 26.83x
Quick Ratio 26.15x
D/E Ratio 0.01x
Financial Leverage 1.07x
Interest Coverage -87.0x
Working Capital $184M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Celldex Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Celldex Therapeutics, Inc.: Free cash flow of $-69M indicates cash challenges that need attention.

Operating Cash Flow $-67M
Free Cash Flow $-69M
Capital Spending $-1M
OCF Growth YoY -4.1%
FCF Growth YoY -9.0%
FCF/Sales -650.9%
CapEx/Sales 30.4%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Celldex Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Celldex Therapeutics, Inc.: An asset turnover of 0.01x suggests room for improvement in asset utilization.

Asset Turnover 0.01x
Receivables Turnover 4.0x
Fixed Assets Turnover 0.6x
Days Sales Outstanding 91 days
Payables Period 234 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Celldex Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Celldex Therapeutics, Inc.: With annual revenue of $5M, Celldex Therapeutics, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $5M
Net Income $-77M
R&D Expense $147M
SG&A Expense $562M
Cost of Goods Sold $57M
Balance Sheet Highlights ($ Millions)
Total Current Assets $92M
Cash & Short-term Investments $90M
Total Liabilities $6M
Short-term Debt $4M
Accounts Receivable $0M
Dividend & Shareholder Information
Dividends Per Share $0.04
Payout Ratio 4.3%
Shares Outstanding 66M
Growth Metrics (YoY)
EPS Growth -11.4%

Latest Celldex Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Celldex Therapeutics, Inc. (CLDX) stock price and investment outlook.

📰 We are currently updating our news feed for Celldex Therapeutics, Inc.. Check back soon for the latest market analysis and company updates.

Celldex Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Celldex Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ACHV Unlock Forecast $145M -3.7x 3.5x
AWH Unlock Forecast $2M -0.5x -0.7x
AWHL Unlock Forecast $15M x x
BMRA Unlock Forecast $5M -0.8x 0.9x
BZYR Unlock Forecast $5M x x
CDIO Unlock Forecast $6M -2.3x 0.6x
CDIOW Unlock Forecast $2M x 0.5x
CLDX Unlock Forecast $1477M -10.1x 2.3x
ICCC Unlock Forecast $55M 31.3x 1.8x
IDXX Unlock Forecast $52710M 53.5x 36.1x
IMDX Unlock Forecast $82M x 8.0x
LNTH Unlock Forecast $4076M 15.0x 3.5x
MYGN Unlock Forecast $560M -8.6x 1.4x
NEOG Unlock Forecast $1211M -145.7x 0.5x
NTLA Unlock Forecast $1225M -2.6x 1.6x
OCX Unlock Forecast $81M -0.7x 7.9x
QDEL Unlock Forecast $1882M -1.6x 0.7x
TKNO Unlock Forecast $254M -8.6x 3.3x
TNFA Unlock Forecast $1M -0.2x 0.1x
VNRX Unlock Forecast $75M 2.7x -2.5x

Frequently Asked Questions - Celldex Therapeutics, Inc. Stock Forecast

How accurate are Celldex Therapeutics, Inc. stock predictions?

Our AI model demonstrates 42% historical accuracy for CLDX predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence Celldex Therapeutics, Inc. stock price forecasts?

Our analysis considers Celldex Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Celldex Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Celldex Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Celldex Therapeutics, Inc. forecasts updated?

Celldex Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Celldex Therapeutics, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Celldex Therapeutics, Inc. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...